Trials / Unknown
UnknownNCT04610125
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, single-arm, prospective，clinical study to evaluate efficacy and safety of Auto CAR-T cell injection in the treatment of recurrent or refractory Hematopoietic and Lymphoid Tissue Tumors in Children
Detailed description
A single car consists of scFv, hinge region, transmembrane region, costimulatory domain and zeta subunit of CD3.Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Auto CAR-T | Biological: Auto CAR-T |
| DRUG | Cyclophosphamide,Fludarabine | Drug: Cyclophosphamide,Fludarabine |
| PROCEDURE | Leukapheresis | Leukapheresis |
Timeline
- Start date
- 2020-06-23
- Primary completion
- 2023-06-22
- Completion
- 2025-06-22
- First posted
- 2020-10-30
- Last updated
- 2020-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04610125. Inclusion in this directory is not an endorsement.